The Question Every NZ Vet Gets Asked About Bravecto — And the Real Answer

If you have been in a New Zealand veterinary clinic in recent years and mentioned Bravecto, you have likely encountered a conversation about social media claims regarding the product’s safety. A campaign circulated claims about Bravecto causing neurological damage and deaths in dogs. These claims were widely shared, generated significant concern, and have persisted online despite thorough investigation by multiple veterinary regulatory bodies internationally, including the relevant authorities in New Zealand. Understanding what those investigations found is important for making informed decisions.

The social media campaign presented anecdotal reports of deaths and serious adverse events in dogs attributed to Bravecto, accompanied by emotional appeals and calls for withdrawal of the product. The volume and emotional intensity of this content led many pet owners to take it seriously. Veterinary professionals worldwide found themselves having to address concerns about a product they had been recommending with confidence – and the investigations that followed were thorough precisely because the concerns were taken seriously by regulators.

What the Investigations Actually Found

The United States FDA, the European Medicines Agency, the Australian APVMA, and MPI in New Zealand all investigated claims about Bravecto and the isoxazoline class of compounds. Their collective finding: isoxazolines as a class have been associated with rare neurological adverse events – tremors, ataxia, seizures – at rates consistent with background neurological event rates in the general dog population. No causal relationship between Bravecto specifically and the patterns of deaths claimed in social media posts was established in any regulatory investigation.

The FDA updated labelling for the entire isoxazoline class to include neurological events as a known rare adverse effect. This is standard regulatory practice when any signal emerges from post-market surveillance, regardless of whether causation has been definitively established. The label update is not evidence of confirmed harm – it is evidence of regulatory diligence. Products continue to be used and recommended globally, including by veterinary professionals in New Zealand who have access to the same literature that informs prescribing decisions worldwide.

The Real Adverse Effect Profile

Bravecto does have documented adverse effects, as all medications do. The most commonly reported following oral administration are mild and transient: vomiting or diarrhoea in some dogs following the first dose, occasional lethargy, and in rare cases skin reactions at topical application sites. These effects are generally self-limiting and resolve within a day or two without treatment. The rare neurological adverse effects noted in regulatory label updates occur at very low incidence and frequently in animals with pre-existing neurological conditions or concurrent medications that may have contributed to the events.

Establishing causation for individual adverse events is genuinely difficult in companion animal medicine. When a dog experiences a seizure days after receiving any medication, the medication may or may not have been causally involved. Background rates of neurological events in the general dog population are not zero – seizure disorders are among the more common neurological presentations in dogs regardless of medication exposure. Attributing every post-treatment event to the most recent treatment is a logical error that the regulatory investigations specifically guarded against.

The Risk-Benefit Framework

Every treatment decision in veterinary medicine involves a risk-benefit analysis. The known, significant, and preventable harms of flea infestations – flea allergy dermatitis affecting quality of life, tapeworm transmission, anaemia in young or small animals, and the substantial welfare cost of chronic skin irritation – must be weighed against the adverse event profile of effective treatments. Untreated flea infestations are not a neutral baseline. They cause real, measurable harm to animals.

New Zealand veterinarians who recommend Bravecto are making this calculation explicitly – not dismissing safety concerns but placing them in appropriate context. The product’s benefit in preventing known, common, significant harm outweighs its risk of rare, largely unconfirmed adverse events for the vast majority of dogs. Individual animals with specific risk factors – pre-existing neurological conditions, known seizure history – warrant case-specific discussion about alternative products.

What to Do If You Have Concerns

If you have specific concerns about Bravecto and your individual dog – particularly a dog with a history of seizures, neurological conditions, or concurrent nervous system medications – discuss this with your veterinarian before starting treatment. Alternative effective products are available and your vet can help select the most appropriate option for your specific animal’s health profile.

For the majority of healthy New Zealand dogs without specific risk factors, the weight of regulatory and clinical evidence supports Bravecto as a safe and effective choice. Source from a reputable pet supply NZ retailer with a valid prescription, follow dosing instructions correctly for your dog’s weight, and monitor your dog normally in the hours following any new medication as good standard practice.

The Role of Social Media in Veterinary Misinformation

The Bravecto social media campaign is a useful case study in how veterinary misinformation spreads and persists. The content followed a recognisable pattern: emotionally compelling individual accounts, requests to share widely, framing of regulatory inaction as evidence of conspiracy, and dismissal of expert opinion as industry capture. These elements were effective at generating shares and concern but are not how product safety evidence is evaluated by the scientists and regulators who investigated the claims.

Understanding this pattern helps pet owners evaluate similar claims about other products in the future. Anecdotal reports of adverse events are not evidence of causation – they are signals worth investigating, which is exactly what regulators did. The investigation process takes time and follows specific methodologies precisely because emotional plausibility is not a reliable guide to causal truth. When independent regulatory agencies in multiple countries investigate and reach similar conclusions, that convergence represents the best available evidence.

Monitoring Your Dog After Any New Medication

Regardless of the product’s established safety record, monitoring your dog in the hours and days following administration of any new medication is good standard practice. Note the time of administration and observe your dog’s normal behaviour. Mild, transient effects – occasional vomiting, brief lethargy – are common first-dose responses to many medications and typically resolve without intervention.

Any neurological signs – tremors, loss of coordination, excessive salivation, seizure activity – in the hours following administration warrant prompt veterinary contact. These events are rare with Bravecto, but prompt reporting to your veterinarian if they occur contributes to the adverse event surveillance data that regulatory bodies use to monitor product safety over time. Source your Bravecto from an authorised